Preclinical Development of mPGES-1 & 5-LOX selective inhibitors for Colon Cancer
Preclinical Development of mPGES-1 & 5-LOX selective inhibitors for Colon Cancer
mPGES-1的临床前开发
批准号：
8571067
负责人：
金额：
$81.95万
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
项目状态：
已结题
起止时间：
2012-09-21 至 2014-09-20
关键词：
AmericanArachidonate 5-LipoxygenaseArachidonic AcidsCancer EtiologyClinical ResearchColon CarcinomaColorectal CancerContractorDevelopmentDiagnosisDoseEpithelialInflammation MediatorsIntestinal NeoplasmsMalignant NeoplasmsMaximum Tolerated DoseMetabolismModelingMusRattusTestingcancer preventioncolorectal cancer preventioninhibitor/antagonistmouse modelpre-clinicalpreclinical studyprostaglandin E synthase-1
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Every year 150,000 Americans are diagnosed with colorectal cancer, the second leading cause of cancer-related mortaliy in the US. Over the past two decases, preclinical and clinical studies and extensive mechanistic studies support the importance of inflammatory mediators, particulary those derived for arachidonic acid metabolism, in the progression of many epithelial cancers, particularly in colorectal cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金